Go back to homepage
| Merck Animal Health | |
| Financial Details | |
| Total Company Revenue in 2010 | $ 46 Bn |
| Revenue from Animal Health Market in 2010 | $ 2.9 Bn |
| % of revenue from Animal Health in 2010 | 6.30% |
| Segmentwise Revenue Breakup ($ Bn) | |
| Livestock Vaccines | 2.233 |
| Companion Vaccines | 0.667 |
| Number of Major Vaccines (Animal-wise) | |
| Poultry | 3 |
| Swine | 1 |
| Fish | 1 |
| Sheep | 1 |
| Cattle | 3 |
| Canine | 1 |
| Feline | 1 |
| Equine | 2 |
| Mergers and Acquisitions (2009 - 2011) | Consideration |
| Schering-Plough | $ 41 Bn |
| Future Focus Areas | |
| Veterinary Vaccines under trial | 0 |
| Future Focus Areas of the company in the Veterinary Vaccines Market | Viral and parasitological vaccines |
| In pharmaceutical R&D, Merck has 120 ongoing projects focusing on parasiticides, anti-infectives and internal medicine (endocrine/pain) and performance products. | |
| In biological R&D, Merck has 140 projects in progress focusing on zoonotic and emerging diseases, respiratory diseases, enteric diseases and enabling technologies. | |
Go back to homepage